Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 1 Study of WVE-007 in Adults Living With Overweight or Obesity
Sponsor: Wave Life Sciences Ltd.
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of WVE-007 when administered subcutaneously (SC) as single ascending doses in adults who are affected by overweight or obesity.
Official title: A Phase 1, Randomized, Double-blind, Placebo-controlled Study of Ascending Doses of WVE-007 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Adults Living With Overweight or Obesity
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
136
Start Date
2025-01-31
Completion Date
2026-10
Last Updated
2026-02-10
Healthy Volunteers
Yes
Conditions
Interventions
WVE-007
Stereopure siRNA oligonucleotide
Locations (6)
Parexel International-EPCU Baltimore
Baltimore, Maryland, United States
ARENSIA Research Clinic
Chisinau, Moldova
Arensia Clinics S.R.L.
Bucharest, Romania
Spitalul Clinic Judetean De Urgenta Cluj
Cluj-Napoca, Romania
Parexel International Early Phase Clinical Unit
Harrow, United Kingdom
Simbec-Orion Clinical Pharmacology
Merthyr Tydfil, United Kingdom